Clinical Trials Logo

Premature Ventricular Complexes clinical trials

View clinical trials related to Premature Ventricular Complexes.

Filter by:
  • None
  • Page 1

NCT ID: NCT05903313 Enrolling by invitation - Clinical trials for Myocardial Infarction

A Study to Evaluate Accuracy and Validity of the Chang Gung ECG Abnormality Detection Software

Start date: October 6, 2023
Phase:
Study type: Observational

"Chang Gung ECG Abnormality Detection Software" is a is an artificial intelligence medical signal analysis software that detect whether patients have abnormal ECG signals of 14 diseases by static 12-lead ECG. The 14 diseases were - Long QT syndrome - Sinus bradycardia - Sinus Tachycardia - Premature atrial complexes - Premature ventricular complexes - Atrial Flutter, Right bundle branch block - Left bundle branch block - Left Ventricular hypertrophy - Anterior wall Myocardial Infarction - Septal wall Myocardial Infarction - Lateral wall Myocardial Infarction - Inferior wall Myocardial Infarction - Posterior wall Myocardial Infarction The main purpose of this study is to verify whether "Chang Gung ECG Abnormality Detection Software" can correctly identify abnormal ECG signals among patients of 14 diseases. The interpretation standard is the consensus of 3 cardiologists. The results of the software analysis will be used to evaluate the performance of the primary and secondary evaluation indicators.

NCT ID: NCT04415203 Recruiting - Clinical trials for Premature Ventricular Complexes

TAES for FPVCs: a Pragmatic, Randomized Controlled Trial

Start date: June 4, 2020
Phase: N/A
Study type: Interventional

This prospective, randomized controlled trial aims to evaluate the efficacy and safety of Transcutaneous Auricular Vagus Nerve Stimulation (TAVNS) for patients with frequent premature ventricular coomplexes (FPVCs). Ninety participants will be randomized to TAVNS group and sham-TAVNS group with the ratio of 1:1. They will receive TAVNS plus usual care or sham-TAVNS plus usual care for 6 weeks, and then be followed up for 12 weeks after the treatment. The primary outcome was the proportion of participants with a 50% decrease of the 24 hour (24h) premature ventricular complexes (PVCs) after 6-week treatment. Secondary outcomes include the proportion of participants with a 75% decrease of the 24h-PVCs; the decrease from baseline of 24h-PVCs, total 24h-heartbeat, and the frequency of supraventricular arrhythmia; the score change from baseline in PVCs-related symptoms; the score change from baseline in SAS and SDS. Subgroup analyses will be performed in age, gender, and the severity of PVCs. Safety assessment will be documented during the whole trial.

NCT ID: NCT00888667 Terminated - Clinical trials for Premature Ventricular Complexes

Optimal EGM Configuration for Morphology Discrimination

SVT Morphology
Start date: April 2009
Phase:
Study type: Observational

The study will be a prospective cohort study of 20 patients recruited from site's Defibrillator Clinic patient population who are followed at the site. Hypothesis: Among the available EGM configuration options, one is better than the others for detection enhancements purposes.